Sorafenib Ameliorates Renal Fibrosis through Inhibition of TGF-β-Induced Epithelial-Mesenchymal Transition
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sorafenib Ameliorates Renal Fibrosis through Inhibition of TGF-β-Induced Epithelial-Mesenchymal Transition
Authors
Keywords
Fibrosis, Kidneys, Apoptosis, Hematoxylin staining, Cell staining, Flow cytometry, Phosphorylation, Immunofluorescence staining
Journal
PLoS One
Volume 10, Issue 2, Pages e0117757
Publisher
Public Library of Science (PLoS)
Online
2015-02-14
DOI
10.1371/journal.pone.0117757
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sorafenib Inhibits Epithelial-Mesenchymal Transition through an Epigenetic-Based Mechanism in Human Lung Epithelial Cells
- (2013) Juyong Zhang et al. PLoS One
- Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats
- (2012) M. D'Amico et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Smad3 linker phosphorylation attenuates Smad3 transcriptional activity and TGF-β1/Smad3-induced epithelial–mesenchymal transition in renal epithelial cells
- (2012) Eunjin Bae et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Strategies for anti-fibrotic therapies
- (2012) Joel Rosenbloom et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
- (2012) C. J. Peer et al. CLINICAL CANCER RESEARCH
- A systems approach identifies HIPK2 as a key regulator of kidney fibrosis
- (2012) Yuanmeng Jin et al. NATURE MEDICINE
- Sorafenib inhibits transforming growth factor β1-Mediated Epithelial-Mesenchymal Transition and apoptosis in mouse hepatocytes
- (2011) Yue-Lei Chen et al. HEPATOLOGY
- Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis
- (2011) Dominique Thabut et al. HEPATOLOGY
- The kinase Pyk2 is involved in renal fibrosis by means of mechanical stretch–induced growth factor expression in renal tubules
- (2011) Kazuhiro Sonomura et al. KIDNEY INTERNATIONAL
- Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells
- (2010) E. Martinelli et al. CLINICAL CANCER RESEARCH
- New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis
- (2010) Yan Wang et al. JOURNAL OF HEPATOLOGY
- Mechanisms of Tubulointerstitial Fibrosis
- (2010) M. Zeisberg et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Smad2 Protects against TGF- /Smad3-Mediated Renal Fibrosis
- (2010) X. M. Meng et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Methylation determines fibroblast activation and fibrogenesis in the kidney
- (2010) Wibke Bechtel et al. NATURE MEDICINE
- Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats
- (2009) Thomas Reiberger et al. JOURNAL OF HEPATOLOGY
- Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats
- (2008) Marc Mejias et al. HEPATOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started